Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 1/2018

CYTOTOXICITY OF INHALABLE DRY POWDERS IN A549 HUMAN LUNG CANCER CELL LINE

ANITA CHVATAL 1, RAMI ALZHRANI 2, AMIT K. TIWARI 2, RITA AMBRUS 1*, PIROSKA SZABÓ-RÉVÉSZ 1, SAI HS. BODDU 2

1.University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, 6720 Szeged, Hungary
2.The University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Frederic and Mary Wolfe Centre, Health Science Campus, 3000 Arlington Avenue, MS 1013, 43614-2595 Toledo, OH, USA
*corresponding author: arita@pharm.u-szeged.hu

Download Full Article PDF

The aim of the present work was to study the cytotoxicity of meloxicam potassium (MP) containing dry powder inhalation systems (DPIs) in monolayers of A549 lung epithelial cells, in order to acquire information on its suitability for pulmonary drug delivery. We also characterized the effect of the used excipients (such as aerosolization enhancer additives and polymers) on the cytotoxicity of the formulated DPIs. We reported for the first time the cytotoxicity of MP in comparison with meloxicam (M) and the results showed that no difference in the safety can be determined at 0.01 and 0.1 mg/mL concentrations. The protective effect of L-leucine was observed in some formulations, while the use of poly-vinyl-alcohol (PVA) decreases this advantage. Comparing the two polymers it can be established that the poly-vinyl-pirrolidon (PVP) is less toxic than the PVA in the same concentrations.